Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Adicionar filtros








Intervalo de ano
1.
Chinese Journal of Experimental Traditional Medical Formulae ; (24): 16-25, 2022.
Artigo em Chinês | WPRIM | ID: wpr-940616

RESUMO

ObjectiveTo study the underlying mechanism of Liuwei Dihuangwan in inhibiting triple-negative breast cancer through mitogen-activated protein kinase kinase kinase 1 (MAPKKK1) and Krüppel-like factor 4 (KLF4). MethodFour hundreds SPF female Kunming mice aged 11.5 months were palpated once every 3 days. The model mice of spontaneous tumors were randomly divided into a model group (normal saline), a paclitaxel group (0.025 g·kg-1·d-1, ip, 21 days), and high-, medium- and low-dose Liuwei Dihuangwan groups (7.2, 3.6, 1.8 g·kg-1·d-1, ig). Tumor tissues were separated until the moribund stage. The tumor volume and weight were measured, and the tumor inhibition rate and the survival time of the tumor mice were calculated (after 6 months, tumor-free mice were assigned into the normal group). SPF SD rats were selected to prepare serum samples containing Liuwei Dihuangwan of different concentrations for cell culture, and MAPKKK1 in MDA-MB-231 cells was silenced. The protein expression of MAPKKK1 and KLF4 was detected by immunofluorescence and Western blot. ResultThe in vivo experimental results showed that compared with the conditions of the normal group, the protein expression of MAPKKK1 and KLF4 in tumor tissues of the model group dropped (P<0.01). Compared with the model group, all medication groups showed reduced tumor volume and weight (P<0.05, P<0.01), increased tumor inhibition rate, prolonged survival time of tumor mice (P<0.05), and increased protein expression of MAPKKK1 (P<0.01). Additionally, the paclitaxel group and the high-dose Liuwei Dihuangwan group exhibited increased protein expression of KLF4 (P<0.01). The in vitro experiments showed that compared with the conditions of the normal group, the fluorescence intensities of MAPKKK1 and KLF4 in MDA-MB-231 cells in all medication groups were potentiated, and the protein expression of MAPKKK1 in the paclitaxel group and the high- and medium-dose Liuwei Dihuangwan groups, and the protein expression of KLF4 in the paclitaxel group and high-dose Liuwei Dihuangwan group increased (P<0.01). After silencing of MAPKKK1, compared with the conditions of the negative plasmid group (unsilenced MAPKKK1), the fluorescence intensities of MAPKKK1 and KLF4 and the protein expression decreased in the RNAi-27 positive plasmid group (silenced MAPKKK1) (P<0.05, P<0.01). Compared with the RNAi-27 positive plasmid group, all medication groups had enhanced fluorescence intensities of MAPKKK1 and KLF4 and protein expression to different degrees (P<0.05, P<0.01). ConclusionLiuwei Dihuangwan can inhibit the growth of triple-negative breast cancer, and the underlying molecular mechanism is related to the up-regulation of MAPKKK1 and activation of KLF4 expression.

2.
Chinese Journal of Experimental Traditional Medical Formulae ; (24): 75-81, 2020.
Artigo em Chinês | WPRIM | ID: wpr-872652

RESUMO

Objective:To explore the potential mechanisms of Panax Notoginseng Saponins (PNS) on growth inhibition of breast cancer cell line 4T1 in tumor-bearing mice by investigating the mitogen-activated protein kinase kinase kinase 1 (MEKK1)/stress activated protein kinase (SAPK)/extracellular regulated protein kinases (Erk) Kinase (SEK1)/c-Jun N-terminal kinase 1 (JNK1)/activator protein-1 (AP-1) signaling pathways. Method:The 4T1 breast cancer mice model was established. Forty-eight mice with successful modeled and randomly divided into the low, medium and high-dose PNS groups (10, 20, 40 mg·kg-1) and the model control group (12 mice in each group). The PNS groups received intraperitoneal injection with dosage of 10 mL·kg-1, while the controlled group was given the same dosage of saline. After administration with PNS for 28 days, tumor tissues were isolated, weighed, sliced and homogenized. Tumor cell apoptosis was detected by TdT mediated-dUTP nick end labeling (TUNEL) staining. The mRNA expressions of MEKK1, SEK1, JNK1 and AP-1 in tumor tissue were detected by Real-time polymerase chain reaction(Real-time PCR). The protein expressions of MEKK1, SEK1, JNK1 and AP-1 in tumor tissue were detected by immunofluorescence staining and Western blot. Result:Compared with model group, the tumor weights of medium-dose and high-dose PNS groups were decreased significantly (P<0.05). TUNEL staining showed that the number of apoptotic tumor cells increased with the rise of dosage of PNS (P<0.05). The medium-dose and high-dose PNS groups showed a significant increase in the mRNA expressions of MEKK1, SEK1, JNK1 and AP-1 as well as the protein expressions of MEKK1, SEK1, JNK1 and AP-1 in tumor tissues (P<0.05), with statistically significant differences (P<0.05). Conclusion:PNS could inhibit the tumor growth of breast cancer cell line 4T1 in tumor-bearing mice, which may be related to the activation of MEKK1/SEK1/JNK1/AP-1 signaling pathways.

3.
Indian J Hum Genet ; 2013 Oct-Dec ;19 (4): 437-442
Artigo em Inglês | IMSEAR | ID: sea-156610

RESUMO

BACKGROUND: Determination of sex is the result of cascade of molecular events that cause undifferentiated bipotential gonad to develop as a testis or an ovary. A series of genes such as SRY, steroidogenic factor‑1 (SF1), AR, SRD5 α, Desert hedgehog (DHH) etc., have been reported to have a significant role in development of sex in the fetus and secondary sexual characteristics at the time of puberty. Recently, mitogen activated protein kinase kinase kinase 1 (MAP3K1) gene was found to be associated with 46, XY disorders of sex development (DSD). AIM: The present study is focused to identify mutations in MAP3K1 gene in the cohort of 10 Indian patients with 46,XY DSD including one family with two affected sisters. These patients were already screened for SRY, SF1 and DHH gene, but no mutation was observed in any of these genes. MATERIALS AND METHODS: The entire coding regions of MAP3K1 were amplified and sequenced using the gene specific primers. RESULTS AND DISCUSSIONS: Sequence analysis of MAP3K1 gene has revealed four variants including one missense, two silent and one deletion mutation. The missense mutation p.D806N was observed in four patients with hypospadias. Two patients showed the presence of silent mutation p.Q1028Q present in exon 14. Another silent mutation p.T428T was observed in a patient with gonadal dysgenesis. We have also observed one deletion mutation p. 942insT present in two patients. The pathogenicity of the missense mutation p.D806N was carried out using in‑silico approach. Sequence homology analysis has revealed that the aspartate at 806 was found to be well‑conserved across species, indicated the importance of this residue. The score for polyphen analysis of this mutation was found to be 0.999 indicating to be pathogenic mutation. Since, p.D806N mutation was found to be important residue; it might contribute to sexual development. We have reported the presence of mutations/polymorphism in MAP3K1 gene. All the mutations were found to be polymorphism upon comparing to single nucleotide polymorphism database. However, in‑silico analysis of the missense mutation revealed to be a pathogenic mutation.


Assuntos
Transtorno 46,XY do Desenvolvimento Sexual/genética , Feminino , Humanos , Índia , MAP Quinase Quinase Quinase 1/química , MAP Quinase Quinase Quinase 1/genética , MAP Quinase Quinase Quinase 1/metabolismo , Masculino , Mutação , Polimorfismo Genético/genética , Irmãos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA